Publikationen
Dr. med. Monika Jermann
| 1 | Eichhorn P, Jermann M Increasing abdominal girth, muscle weakness and ecchymoses. Adrenal cortex carcinoma with liver metastases. Schweiz Med Wochenschrift 1999 Jan 23;129(3):90This is some text inside of a div block. |
| 2 | Jermann M, Hiersemenzel LP, Waespe W Drug-dependent patient with multiple skin abscesses and wound botulism. Schweiz Med Wochenschrift 1999 Oct 9;129(40):1467 |
| 3 | Hiersemenzel LP, Jermann M, Waespe W Deszendierende Lähmung durch Wundbotulismus Der Nervenarzt 2000, 71:130-133. |
| 4 | T. Boehm, M. Jermann, P. Jungius, M. Kurrer Non Hodgkin Lymphoma of the Pleural Cavity. Eurorad Case 724: 2000, Nov 21 |
| 5 | Jermann M, Wettstein T, Attenhofer Ch Ungewöhnliche EKG-Veränderungen bei Angina pectoris. Swiss Medical Forum 2001 April 25;17:439-40. |
| 6 | Jermann M, Eid K, Pfammatter T, Stahel R Images in Cardiovascular Medicine. Maffucci`s Syndrome. Circulation 2001;104:1693 |
| 7 | Trojan A, Jermann M, Taverna Ch, Hany TF Fusion PET-CT imaging of Neurolymphomatosis. Annals of Oncology 2002,13:802-805 |
| 8 | Jermann M, Waespe W Hirntot.. oder? Die Locked-in Variante des Guillain Barré Syndroms Swiss Medical Forum 2003;3:342-345 |
| 9 | Jermann M, Vogt P, Pestalozzi B Case Report. Peritoneal carcinoma in a Male Patient. Oncology 2003;64:468-472 |
| 10 | Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner Th, Stahel RA Rituximab-EPOCH, an Effective Salvage Therapy for Relapsed, Refractory, or Transformed B-Cell Lymphomas: Results of a Phase II Study. Annals of Oncology 2004; 15:511-516 |
| 11 | Jermann M, Jost LM, Taverna Ch, Jacky E, Honegger HP, Betticher DC, Egli F, Kroner Th, Stahel RA Rituximab-EPOCH, an Effective Salvage Therapy for Relapsed, Refractory, or Transformed B-Cell Lymphomas: Results of a Phase II Study. Annals of Oncology 2004; 15:511-516 |
| 12 | Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D,Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. Circulating Deoxyribonucleic Acid As Prognostic Marker in Non-Small-Cell Lung Cancer Patients undergoing Chemotherapy J Clin Oncol 2004; 22(20): 4157-64. |
| 13 | Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M A Phase II, Open-Label Study of Gefitinib (Iressa) in Patients with Locally Advanced, Metastatic, or Relapsed Renal-Cell Carcinoma Cancer Chemotherapy and Pharmacology 2005 Jul 29;:1-7 [Epub ahead of print] |
| 14 | Khani H, Jermann M, Jost L Der besondere Fall: Eine ungewöhnliche Nebenwirkung einer Antikörper-Behandlung Schweiz Med Forum 2005;5:1035-37 |
| 15 | Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers N, Ratschiller D, Jermann M, Stahel RA, Heighway J, Betticher DC CCND1 (Cyclin D1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Lung Cancer 2006 Mar;51(3):303-11. Epub 2006 Jan 10. |
| 16 | Stahel RA, Weder W, Bernhard J, Bodis S, Vogt W, Ballabeni P, Lardinois D, Jermann M, Betticher D, Schmid R, Stupp R, Ris HB, Mingrone W, Roth A, Spiliopoulos A Multicenter study of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma Annals of Oncology 2007 Apr 11 (Epub ahead of print) |
| 17 | Collecutt J, Jermann M, Willi N, Jost LM Der besondere Fall: Blindheit durch ein Mantelzell-Lymphom Schweiz Med Forum 2007;22:485-87 |